Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system
Peter A.S. Johnstone(Naval Medical Center San Diego), Christopher L. Amling(Oregon Health & Science University), Christopher J. Kane(University of California San Diego), Timothy F. Donahue(Memorial Sloan Kettering Cancer Center), Judd W. Moul(General Marble (Greece)), Leon Sun(Madigan Army Medical Center), Jason Do(Naval Medical Center San Diego), Robert H. Riffenburgh(Naval Medical Center San Diego), John B. Foley(Naval Medical Center San Diego), Andrew Chung(Madigan Army Medical Center), Douglas Martin(Naval Medical Center San Diego), Michael G. Beat(Naval Medical Center San Diego), Hongyu Wu(Qingdao University), Raymond Lance(Madigan Army Medical Center), David G. McLeod(George Washington University), Leo Kusuda(Madigan Army Medical Center), Robert G. Douglas(Naval Medical Center San Diego), Douglas W. Soderdahl(Eisenhower Medical Center)
International Journal of Radiation Oncology*Biology*Physics
March 1, 2003
Cited by 27
Related Papers
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
|The Journal of Urology|2007|1.1k
Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes
|The Journal of Urology|2007|845
Prostate Cancer, Version 1.2016
|Journal of the National Comprehensive Cancer Network|2016|656